Ind-Swift Laboratories Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 1:45 pm

Market Cap	603 Cr.
Current Price	102
High / Low	186/81.5
Stock P/E	7.28
Book Value	171
Dividend Yield	0.00 %
ROCE	19.6 %
ROE	17.4 %
Face Value	10.0
PEG Ratio	0.06

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Ind-Swift Laboratories Ltd

Competitors of Ind-Swift Laboratories Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.05 Cr.	3.69	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	51.9 Cr.	70.0	94.9/32.1	17.6	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	39.6 Cr.	27.0	29.0/8.74	40.4	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	76.2 Cr.	101	155/79.0	12.3	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,471.89 Cr	1,089.07		42.69	185.80	0.36%	16.00%	16.32%	6.27

All Competitor Stocks of Ind-Swift Laboratories Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	246.64	306.65	280.17	310.21	312.69	304.25	310.34	289.71	287.51	393.33	33.17	11.96	8.66
Expenses	194.25	269.95	227.16	251.45	258.93	240.58	250.05	224.02	235.82	316.81	42.91	23.76	23.20
Operating Profit	52.39	36.70	53.01	58.76	53.76	63.67	60.29	65.69	51.69	76.52	-9.74	-11.80	-14.54
OPM %	21.24%	11.97%	18.92%	18.94%	17.19%	20.93%	19.43%	22.67%	17.98%	19.45%	-29.36%	-98.66%	-167.90%
Other Income	8.41	21.21	7.39	7.54	8.36	-16.44	5.61	7.40	7.11	411.84	11.14	13.01	13.81
Interest	23.73	23.49	23.98	23.98	22.38	21.82	20.38	21.14	21.05	-11.47	0.17	0.41	0.11
Depreciation	21.26	81.81	16.28	16.41	15.39	9.29	13.89	13.19	13.56	12.67	0.25	0.22	0.25
Profit before tax	15.81	-47.39	20.14	25.91	24.35	16.12	31.63	38.76	24.19	487.16	0.98	0.58	-1.09
Tax %	-1.39%	29.65%	1.09%	2.16%	-13.43%	255.40%	45.02%	17.88%	19.31%	27.60%	-3.06%	31.03%	-99.08%
Net Profit	16.03	-61.45	19.88	25.34	27.50	-25.12	17.24	31.66	19.42	352.64	0.94	0.41	0.01
EPS in Rs	2.71	-10.40	3.36	4.29	4.65	-4.25	2.92	5.36	3.29	59.68	0.16	0.07	0.00

Last Updated: February 28, 2025, 7:15 pm

Below is a detailed analysis of the quarterly data for Ind-Swift Laboratories Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹8.66 Cr.. The value appears to be declining and may need further review. It has decreased from 11.96 Cr. (Sep 2024) to ₹8.66 Cr., marking a decrease of 3.30 Cr..
For Expenses, as of Dec 2024, the value is ₹23.20 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 23.76 Cr. (Sep 2024) to ₹23.20 Cr., marking a decrease of 0.56 Cr..
For Operating Profit, as of Dec 2024, the value is ₹-14.54 Cr.. The value appears to be declining and may need further review. It has decreased from -11.80 Cr. (Sep 2024) to ₹-14.54 Cr., marking a decrease of 2.74 Cr..
For OPM %, as of Dec 2024, the value is -167.90%. The value appears to be declining and may need further review. It has decreased from -98.66% (Sep 2024) to -167.90%, marking a decrease of 69.24%.
For Other Income, as of Dec 2024, the value is ₹13.81 Cr.. The value appears strong and on an upward trend. It has increased from 13.01 Cr. (Sep 2024) to ₹13.81 Cr., marking an increase of ₹0.80 Cr..
For Interest, as of Dec 2024, the value is ₹0.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.41 Cr. (Sep 2024) to ₹0.11 Cr., marking a decrease of 0.30 Cr..
For Depreciation, as of Dec 2024, the value is ₹0.25 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.22 Cr. (Sep 2024) to ₹0.25 Cr., marking an increase of ₹0.03 Cr..
For Profit before tax, as of Dec 2024, the value is ₹-1.09 Cr.. The value appears to be declining and may need further review. It has decreased from 0.58 Cr. (Sep 2024) to ₹-1.09 Cr., marking a decrease of 1.67 Cr..
For Tax %, as of Dec 2024, the value is -99.08%. The value appears to be improving (decreasing) as expected. It has decreased from 31.03% (Sep 2024) to -99.08%, marking a decrease of 130.11%.
For Net Profit, as of Dec 2024, the value is ₹0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.41 Cr. (Sep 2024) to ₹0.01 Cr., marking a decrease of 0.40 Cr..
For EPS in Rs, as of Dec 2024, the value is 0.00. The value appears to be declining and may need further review. It has decreased from ₹0.07 (Sep 2024) to 0.00, marking a decrease of ₹0.07.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:56 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	1,134	965	660	653	716	765	757	780	891	1,039	1,207	1,281	447
Expenses	1,063	906	571	546	610	631	630	635	709	837	978	1,029	407
Operating Profit	72	59	89	107	106	134	126	144	183	202	229	252	40
OPM %	6%	6%	13%	16%	15%	18%	17%	19%	21%	19%	19%	20%	9%
Other Income	4	-19	-31	1	15	16	120	33	23	37	7	434	450
Interest	140	117	117	106	88	28	92	107	100	96	92	51	-11
Depreciation	54	66	84	85	88	87	104	90	87	131	57	53	13
Profit before tax	-119	-142	-143	-83	-55	36	50	-20	18	13	87	582	488
Tax %	-1%	-14%	-17%	-29%	-29%	39%	42%	7%	117%	117%	45%	28%
Net Profit	-118	-122	-119	-59	-39	22	29	-21	-3	-2	48	421	354
EPS in Rs	-30.02	-29.79	-29.14	-14.33	-8.75	4.85	6.09	-3.59	-0.53	-0.36	8.06	71.24	59.91
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-3.39%	2.46%	50.42%	33.90%	156.41%	31.82%	-172.41%	85.71%	33.33%	2500.00%	777.08%
Change in YoY Net Profit Growth (%)	0.00%	5.85%	47.96%	-16.52%	122.51%	-124.59%	-204.23%	258.13%	-52.38%	2466.67%	-1722.92%

Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	3%
5 Years:	11%
3 Years:	13%
TTM:	-62%

Compounded Profit Growth
10 Years:	14%
5 Years:	42%
3 Years:	260%
TTM:	188%

Stock Price CAGR
10 Years:	12%
5 Years:	43%
3 Years:	11%
1 Year:	-8%

Return on Equity
10 Years:	0%
5 Years:	5%
3 Years:	10%
Last Year:	17%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:25 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	39	41	42	42	45	46	48	60	60	60	60	59	59
Reserves	814	684	553	476	486	507	540	581	544	541	622	872	952
Borrowings	1,240	1,355	1,413	1,457	1,242	1,083	1,148	1,031	1,005	953	862	17	16
Other Liabilities	280	258	236	240	364	387	188	198	210	247	280	217	160
Total Liabilities	2,374	2,339	2,244	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,165	1,188
Fixed Assets	1,171	1,174	1,117	1,099	1,042	934	914	843	753	630	587	8	7
CWIP	161	78	113	78	70	69	20	11	19	10	8	0	0
Investments	17	17	18	18	18	18	19	17	36	29	30	111	192
Other Assets	1,025	1,070	997	1,020	1,007	1,002	972	998	1,011	1,131	1,199	1,047	989
Total Assets	2,374	2,339	2,244	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,165	1,188

Below is a detailed analysis of the balance sheet data for Ind-Swift Laboratories Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹59.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹59.00 Cr..
For Reserves, as of Sep 2024, the value is ₹952.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹872.00 Cr. (Mar 2024) to ₹952.00 Cr., marking an increase of 80.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹16.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹17.00 Cr. (Mar 2024) to ₹16.00 Cr., marking a decrease of 1.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹160.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹217.00 Cr. (Mar 2024) to ₹160.00 Cr., marking a decrease of 57.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹1,188.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,165.00 Cr. (Mar 2024) to ₹1,188.00 Cr., marking an increase of 23.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹7.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹8.00 Cr. (Mar 2024) to ₹7.00 Cr., marking a decrease of 1.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹192.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹111.00 Cr. (Mar 2024) to ₹192.00 Cr., marking an increase of 81.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹989.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,047.00 Cr. (Mar 2024) to ₹989.00 Cr., marking a decrease of 58.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹1,188.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,165.00 Cr. (Mar 2024) to ₹1,188.00 Cr., marking an increase of 23.00 Cr..

Notably, the Reserves (₹952.00 Cr.) exceed the Borrowings (16.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-47	0	98	79	96	73	-64	125	135	150	195	-163
Cash from Investing Activity +	-48	0	-35	-29	-31	-17	-12	-9	-10	5	-13	-104
Cash from Financing Activity +	66	0	-64	-48	-69	-62	100	-133	-124	-141	-186	699
Net Cash Flow	-29	0	-1	3	-4	-6	23	-17	1	14	-4	431

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	71.00	58.00	88.00	106.00	105.00	133.00	125.00	143.00	182.00	-751.00	-633.00	235.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	133	168	215	208	182	194	169	186	177	160	153	48
Inventory Days	180	182	312	368	305	291	284	315	301	288	242	6
Days Payable	81	103	120	137	91	118	114	124	111	118	113	52
Cash Conversion Cycle	232	247	407	439	396	367	339	377	367	330	282	2
Working Capital Days	246	277	379	255	110	99	305	313	303	290	267	4
ROCE %	2%	0%	1%	2%	2%	4%	4%	5%	7%	7%	13%	20%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	42.00%	42.00%	42.01%	42.01%	42.01%	42.01%	42.01%	42.01%	42.01%	42.01%	42.01%	42.01%
FIIs	0.06%	0.00%	0.00%	0.04%	0.00%	0.08%	0.17%	0.31%	0.26%	1.27%	0.65%	0.46%
DIIs	19.49%	19.49%	19.49%	19.49%	19.49%	19.49%	19.49%	18.73%	8.03%	0.94%	0.94%	0.94%
Public	38.44%	38.50%	38.51%	38.48%	38.52%	38.44%	38.34%	38.96%	49.72%	55.81%	56.41%	56.61%
No. of Shareholders	25,342	24,910	24,226	24,456	23,397	22,962	25,405	24,633	22,439	25,461	28,883	28,752

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	71.24	8.10	-0.36	-0.53	-4.28
Diluted EPS (Rs.)	71.24	8.10	-0.36	-0.53	-4.28
Cash EPS (Rs.)	80.35	17.59	21.55	14.07	11.52
Book Value[Excl.RevalReserv]/Share (Rs.)	157.64	83.36	67.61	65.66	69.48
Book Value[Incl.RevalReserv]/Share (Rs.)	157.64	114.02	100.47	100.90	107.12
Revenue From Operations / Share (Rs.)	216.78	201.87	173.68	149.04	130.36
PBDIT / Share (Rs.)	50.70	43.92	39.98	34.36	29.73
PBIT / Share (Rs.)	41.68	34.33	18.07	19.77	14.67
PBT / Share (Rs.)	98.46	14.47	2.10	3.01	-3.31
Net Profit / Share (Rs.)	71.33	8.00	-0.35	-0.52	-3.54
NP After MI And SOA / Share (Rs.)	71.24	7.96	-0.35	-0.52	-3.54
PBDIT Margin (%)	23.38	21.75	23.01	23.05	22.80
PBIT Margin (%)	19.22	17.00	10.40	13.26	11.25
PBT Margin (%)	45.41	7.16	1.20	2.02	-2.53
Net Profit Margin (%)	32.90	3.96	-0.20	-0.35	-2.71
NP After MI And SOA Margin (%)	32.86	3.94	-0.20	-0.35	-2.71
Return on Networth / Equity (%)	45.19	9.54	-0.53	-0.80	-5.09
Return on Capital Employeed (%)	26.09	14.13	7.36	7.86	5.67
Return On Assets (%)	36.13	2.60	-0.11	-0.17	-1.13
Long Term Debt / Equity (X)	0.01	1.51	2.10	2.25	2.14
Total Debt / Equity (X)	0.01	1.73	2.35	2.56	2.48
Asset Turnover Ratio (%)	0.85	0.66	0.54	0.46	0.39
Current Ratio (X)	2.99	3.14	3.22	3.00	2.67
Quick Ratio (X)	2.94	1.96	1.94	1.81	1.61
Inventory Turnover Ratio (X)	2.67	1.52	1.33	1.23	1.19
Interest Coverage Ratio (X)	5.86	2.85	2.50	2.05	1.65
Interest Coverage Ratio (Post Tax) (X)	1.68	1.81	0.97	0.96	0.80
Enterprise Value (Cr.)	165.50	1173.71	1328.01	1424.06	1150.03
EV / Net Operating Revenue (X)	0.12	0.97	1.28	1.60	1.48
EV / EBITDA (X)	0.55	4.47	5.55	6.93	6.47
MarketCap / Net Operating Revenue (X)	0.45	0.27	0.38	0.48	0.16
Price / BV (X)	0.62	0.66	0.98	1.10	0.31
Price / Net Operating Revenue (X)	0.45	0.27	0.38	0.48	0.16
EarningsYield	0.72	0.14	-0.01	-0.01	-0.16

After reviewing the key financial ratios for Ind-Swift Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 71.24. This value is within the healthy range. It has increased from 8.10 (Mar 23) to 71.24, marking an increase of 63.14.
For Diluted EPS (Rs.), as of Mar 24, the value is 71.24. This value is within the healthy range. It has increased from 8.10 (Mar 23) to 71.24, marking an increase of 63.14.
For Cash EPS (Rs.), as of Mar 24, the value is 80.35. This value is within the healthy range. It has increased from 17.59 (Mar 23) to 80.35, marking an increase of 62.76.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 157.64. It has increased from 83.36 (Mar 23) to 157.64, marking an increase of 74.28.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 157.64. It has increased from 114.02 (Mar 23) to 157.64, marking an increase of 43.62.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 216.78. It has increased from 201.87 (Mar 23) to 216.78, marking an increase of 14.91.
For PBDIT / Share (Rs.), as of Mar 24, the value is 50.70. This value is within the healthy range. It has increased from 43.92 (Mar 23) to 50.70, marking an increase of 6.78.
For PBIT / Share (Rs.), as of Mar 24, the value is 41.68. This value is within the healthy range. It has increased from 34.33 (Mar 23) to 41.68, marking an increase of 7.35.
For PBT / Share (Rs.), as of Mar 24, the value is 98.46. This value is within the healthy range. It has increased from 14.47 (Mar 23) to 98.46, marking an increase of 83.99.
For Net Profit / Share (Rs.), as of Mar 24, the value is 71.33. This value is within the healthy range. It has increased from 8.00 (Mar 23) to 71.33, marking an increase of 63.33.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 71.24. This value is within the healthy range. It has increased from 7.96 (Mar 23) to 71.24, marking an increase of 63.28.
For PBDIT Margin (%), as of Mar 24, the value is 23.38. This value is within the healthy range. It has increased from 21.75 (Mar 23) to 23.38, marking an increase of 1.63.
For PBIT Margin (%), as of Mar 24, the value is 19.22. This value is within the healthy range. It has increased from 17.00 (Mar 23) to 19.22, marking an increase of 2.22.
For PBT Margin (%), as of Mar 24, the value is 45.41. This value is within the healthy range. It has increased from 7.16 (Mar 23) to 45.41, marking an increase of 38.25.
For Net Profit Margin (%), as of Mar 24, the value is 32.90. This value exceeds the healthy maximum of 10. It has increased from 3.96 (Mar 23) to 32.90, marking an increase of 28.94.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 32.86. This value exceeds the healthy maximum of 20. It has increased from 3.94 (Mar 23) to 32.86, marking an increase of 28.92.
For Return on Networth / Equity (%), as of Mar 24, the value is 45.19. This value is within the healthy range. It has increased from 9.54 (Mar 23) to 45.19, marking an increase of 35.65.
For Return on Capital Employeed (%), as of Mar 24, the value is 26.09. This value is within the healthy range. It has increased from 14.13 (Mar 23) to 26.09, marking an increase of 11.96.
For Return On Assets (%), as of Mar 24, the value is 36.13. This value is within the healthy range. It has increased from 2.60 (Mar 23) to 36.13, marking an increase of 33.53.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 1.51 (Mar 23) to 0.01, marking a decrease of 1.50.
For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 1.73 (Mar 23) to 0.01, marking a decrease of 1.72.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.85. It has increased from 0.66 (Mar 23) to 0.85, marking an increase of 0.19.
For Current Ratio (X), as of Mar 24, the value is 2.99. This value is within the healthy range. It has decreased from 3.14 (Mar 23) to 2.99, marking a decrease of 0.15.
For Quick Ratio (X), as of Mar 24, the value is 2.94. This value exceeds the healthy maximum of 2. It has increased from 1.96 (Mar 23) to 2.94, marking an increase of 0.98.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.67. This value is below the healthy minimum of 4. It has increased from 1.52 (Mar 23) to 2.67, marking an increase of 1.15.
For Interest Coverage Ratio (X), as of Mar 24, the value is 5.86. This value is within the healthy range. It has increased from 2.85 (Mar 23) to 5.86, marking an increase of 3.01.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.68. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 23) to 1.68, marking a decrease of 0.13.
For Enterprise Value (Cr.), as of Mar 24, the value is 165.50. It has decreased from 1,173.71 (Mar 23) to 165.50, marking a decrease of 1,008.21.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.97 (Mar 23) to 0.12, marking a decrease of 0.85.
For EV / EBITDA (X), as of Mar 24, the value is 0.55. This value is below the healthy minimum of 5. It has decreased from 4.47 (Mar 23) to 0.55, marking a decrease of 3.92.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.27 (Mar 23) to 0.45, marking an increase of 0.18.
For Price / BV (X), as of Mar 24, the value is 0.62. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 23) to 0.62, marking a decrease of 0.04.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.27 (Mar 23) to 0.45, marking an increase of 0.18.
For EarningsYield, as of Mar 24, the value is 0.72. This value is below the healthy minimum of 5. It has increased from 0.14 (Mar 23) to 0.72, marking an increase of 0.58.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Ind-Swift Laboratories Ltd as of March 11, 2025 is: ₹176.75

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 11, 2025, Ind-Swift Laboratories Ltd is Undervalued by 73.28% compared to the current share price 102.00

Intrinsic Value of Ind-Swift Laboratories Ltd as of March 11, 2025 is: 402.76

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 11, 2025, Ind-Swift Laboratories Ltd is Undervalued by 294.86% compared to the current share price 102.00

Last 5 Year EPS CAGR: 127.87%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has shown consistent growth in sales (510.62 cr) and profit (54.77 cr) over the years.	The stock has a low average ROCE of 5.58%, which may not be favorable. The stock has a high average Working Capital Days of 237.33, which may not be favorable. The stock has a high average Cash Conversion Cycle of 315.42, which may not be favorable. The company has higher borrowings (986.31) compared to reserves (628.62), which may suggest financial risk.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
1. Net Profit Margin: 32.9%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 26.09% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 45.19% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 1.68
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.94
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 7.28 (Industry average Stock P/E: 42.69)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

No data availabale for About the Company

INDUSTRY	ADDRESS	CONTACT
Industry not found	Address not found	Contact not found

Management Data not Available

FAQ

What is the latest intrinsic value of Ind-Swift Laboratories Ltd?

The latest intrinsic value of Ind-Swift Laboratories Ltd as on 10 March 2025 is ₹176.75, which is 73.28% higher than the current market price of 102.00, indicating the stock is undervalued by 73.28%. The intrinsic value of Ind-Swift Laboratories Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹603 Cr. and recorded a high/low of ₹186/81.5 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹952 Cr and total liabilities of ₹1,188 Cr.

What is the Market Cap of Ind-Swift Laboratories Ltd?

The Market Cap of Ind-Swift Laboratories Ltd is 603 Cr..

What is the current Stock Price of Ind-Swift Laboratories Ltd as on 10 March 2025?

The current stock price of Ind-Swift Laboratories Ltd as on 10 March 2025 is ₹102.

What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Ind-Swift Laboratories Ltd stocks is ₹186/81.5.

What is the Stock P/E of Ind-Swift Laboratories Ltd?

The Stock P/E of Ind-Swift Laboratories Ltd is 7.28.

What is the Book Value of Ind-Swift Laboratories Ltd?

The Book Value of Ind-Swift Laboratories Ltd is 171.

What is the Dividend Yield of Ind-Swift Laboratories Ltd?

The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.

What is the ROCE of Ind-Swift Laboratories Ltd?

The ROCE of Ind-Swift Laboratories Ltd is 19.6 %.

What is the ROE of Ind-Swift Laboratories Ltd?

The ROE of Ind-Swift Laboratories Ltd is 17.4 %.

What is the Face Value of Ind-Swift Laboratories Ltd?

The Face Value of Ind-Swift Laboratories Ltd is 10.0.